Valsartan Mass Tort Case Leads
Connect with patients who developed cancer after taking blood pressure medication contaminated with the probable carcinogens NDMA and NDEA.
Valsartan, Losartan, and Irbesartan NDMA Contamination Lawsuits
Beginning in 2018, the FDA announced a cascading series of recalls of valsartan, losartan, and irbesartan — widely prescribed 'sartan' blood pressure and heart failure medications — after testing found N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA), both classified as probable human carcinogens, in product manufactured by overseas generic drugmakers including Zhejiang Huahai (ZHP), Hetero, Teva, Torrent, and Aurobindo. Lawsuits allege the contamination resulted from manufacturing process changes and inadequate quality control, and that patients ingested the carcinogens daily for years. Federal claims are consolidated in MDL 2875 in the District of New Jersey, with roughly 1,400 cases pending as of July 2026. A separate economic-loss settlement covering refund-type claims received preliminary approval in February 2026 — personal injury and medical monitoring claims were expressly excluded from it and remain in active litigation, with no settlement in place with ZHP, Teva, or Torrent.
Associated Conditions
- Liver cancer
- Stomach or gastric cancer
- Colorectal cancer
- Esophageal cancer
- Pancreatic cancer
- Bladder or kidney cancer
- Prostate and lung cancers alleged in the litigation
Claimant Eligibility
- Took valsartan, losartan, or irbesartan from a recalled manufacturer or lot, generally between 2012 and 2019
- Diagnosed with one of the cancers associated with NDMA or NDEA exposure
- Pharmacy records or prescription history documenting the specific generic manufacturer and duration of use
- Diagnosis followed a sustained period of use rather than a brief or one-off prescription
- Personal injury claim — economic-loss refund claims were resolved separately and are not part of this campaign
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Valsartan legal marketing campaigns: how we acquire cases
Valsartan case acquisition runs as a multi-channel program, not a single ad buy. Product liability and class action claimants research their condition long before they contact a lawyer, so we meet potential clients at each stage — paid demand capture for people already searching, paid social and traditional media for people who have not yet connected their injury to the litigation, and organic search for the long research tail.
Digital marketing channels
- Google Ads and paid search demand capture
- Meta and paid social prospecting by exposure profile
- Mass tort search engine optimization for the research tail
- OTT and connected TV retargeting
Traditional media channels
- Broadcast and cable TV in qualifying DMAs
- Radio and streaming audio
- Direct response print in occupational verticals
- Earned media and litigation PR support
How the channel mix is built, budgeted, and measured is covered in our mass tort marketing guide. For intake handling once the lead lands, see mass tort intake.
Running a Valsartan mass tort marketing campaign
Common questions from law firms about Valsartan lawsuit lead generation and campaign management.
- What does a Valsartan mass tort marketing campaign include?
- A Valsartan mass tort marketing campaign from Mass Tort Marketing Agency covers multi-channel strategy across Meta, Google PPC, OTT and connected TV, traditional media, and mass tort search engine optimization; compliant ad creative; TCPA-verified intake; claimant qualification against your Valsartan case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- How do you generate Valsartan mass tort case leads?
- Valsartan mass tort case leads are generated through paid social and search campaigns aimed at the specific exposure and injury profile of the litigation, supported by organic content that captures claimants already researching their condition. Every lead is a real, consented claimant — we do not buy aggregated lists or resell shared data.
- What do Valsartan legal marketing campaigns cost?
- Valsartan legal marketing campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. Cost per retainer varies by tort based on claimant prevalence, media competition, and how tight your case criteria are. We scope a per-tort figure before any spend commitment.
- Are Valsartan leads exclusive to my firm?
- Yes. Every Valsartan lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Valsartan claimants qualified before delivery?
- Each Valsartan claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a certified TrustedForm or Jornaya consent record — preserving the exact disclosure language shown at submission — before the lead reaches your intake team.
- How fast can a Valsartan case acquisition program scale?
- A Valsartan mass tort case acquisition program typically moves from scoping to live media inside two weeks, with volume ramped against your docket capacity rather than pushed to a fixed budget. Volume can be scaled up or down by tort month to month as the litigation posture changes.
- Do valsartan campaigns qualify claimants on the specific generic manufacturer?
- Yes. Only certain manufacturers and lots were implicated in the NDMA and NDEA recalls, so 'took valsartan' is not by itself a qualifying fact. Intake works to establish the dispensing pharmacy, the generic manufacturer on the label, and the fill dates, alongside the cancer diagnosis and pathology. Files that cannot be tied to a recalled manufacturer are screened out before delivery — your firm makes the final eligibility determination.
- Does the 2026 economic-loss settlement affect personal injury campaigns?
- No. The economic-loss settlement that received preliminary approval in February 2026 covers refund-type claims for the cost of the contaminated medication and expressly excludes personal injury and medical monitoring claims. Cancer claims remain in active litigation in MDL 2875, and campaigns are built exclusively around that personal injury track.
Get Valsartan campaign pricing on a 30-minute call
We will walk your Valsartan case criteria, current cost per signed retainer, and the volume your docket can absorb — and tell you plainly if this tort is not a fit right now.
See how every lead is qualified on our mass tort leads page, read the full mass tort marketing guide, or compare providers in our top mass tort marketing firms guide.